Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...

Genentech, part of the Roche (ROG SIX) group, has received a new approval from the US Food and Drug Administration for TNKase ...

Omalizumab is superior to oral immunotherapy (OIT) for multifood allergy, and most patients include dietary consumption (DC) ...

Roche announces positive results from phase III OUtMATCH study of Xolair for the treatment of one or more food allergies: Basel Tuesday, March 4, 2025, 12:00 Hrs [IST] Roche annou ...

Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

Genentech, a member of the Roche Group, announced that the FDA has approved the company’s TNKase (tenecteplase) thrombolytic ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

Just nine weeks after UnitedHealthcare CEO Brian Thompson was murdered on a weekday morning on a busy street, the luminaries ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

Biotech-focused investment firm Frazier Life Sciences launched Callio Therapeutics, a cancer treatment startup with ...

Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...